Dec 09, 2019: Healx the AI-powered biotechnology company, announces that it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
This project will influence Healx’s comprehensive AI-based drug discovery platform, Healnet and expertise in rare diseases and pharmacology, in order to identify potential new indications for assets from Boehringer Ingelheim’s pipeline.
Healx will use their data analysis and technological capabilities in order to support Boehringer Ingelheim’s efforts in prioritising selected indications for advance research.
Healx has remarkable experience in the area of numerous rare neurological disorders, such as fragile X syndrome as well as Pitt-Hopkins syndrome.
Healnet successfully used to investigate, predict and progress new treatment options for the ultra-rare neuro developmental disorder Pitt-Hopkins syndrome.
The project with Boehringer Ingelheim adds to Healx’s portfolio of agreements and collaborations with the Pharmaceutical and Biotechnology companies, academia, Clinical Institutes and rare disease charities while its foundation in 2014. https://healx.io/news/healx-joins-forces-with-boehringer-ingelheim-to-discover-new-treatment-approaches-for-rare-neurological-diseases/
